Clinical Trials Logo

Nasopharyngeal Carcinoma clinical trials

View clinical trials related to Nasopharyngeal Carcinoma.

Filter by:

NCT ID: NCT06268600 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

This study aimed to reduce radiation-induced thyroid injury without compromising control of the cervical region by optimizing the delineation of the cervical lymph node drainage area.

NCT ID: NCT06265844 Recruiting - Dysphagia Clinical Trials

Multifunctional Nutrition Tube in Dysphagia for Nasopharyngeal Carcinoma

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

This is a prospective multicenter study with patients with delayed dysphagia after radiotherapy for NPC. Patients enrolled are randomly divided equally into the observation group and the control group. All patients receive conventional care, and the observation group received IOE while the control group received NGT for enteral nutrition support. Baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life (QOL) after treatment as well as adverse events are compared.

NCT ID: NCT06259721 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Start date: February 10, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the efficacy and safety of a combination regimen of Anti-PD1 monoclonal antibody, nimotuzumab, and capecitabin in treating recurrent or metastatic nasopharyngeal carcinoma patients who have failed first-line platinum-based chemotherapy.

NCT ID: NCT06241612 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Individualized Elective Neck Irradiation in NPC Patients

Start date: April 16, 2024
Phase: Phase 3
Study type: Interventional

To evaluate whether individualized elective neck irradiation for nasopharyngeal carcinoma based on the vertebral level of metastatic lymph nodes can reduce the incidence of radiation-related adverse effects and improve patients' quality of life,without reducing survival.

NCT ID: NCT06241599 Recruiting - Clinical trials for Recurrent or Metastatic Nasopharyngeal Carcinoma

A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Start date: February 1, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

To compare whether AK104 combined with GP or PFLL can improve survival benefit, safety and tolerability in nasopharyngeal carcinoma patients who have failed first-line treatment; To compare the survival benefits of GP or GFLL treatment in nasopharyngeal carcinoma patients who had failed first-line therapy; To compare the survival benefits of GP or GFLL combined with AK104 in patients with nasopharyngeal carcinoma who had failed first-line therapy.

NCT ID: NCT06239727 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Start date: March 1, 2024
Phase: Phase 3
Study type: Interventional

This is an Open Label, Non-Inferiority, Multicenter, Randomized Phase 3 Trial aimed to investigate the impact of reduced-dose radiotherapy in combination with chemotherapy and immunotherapy on patients' prognosis and complication compared with conventional-dose radiotherapy in combination with chemotherapy and immunotherapy for treatment-sensitive stage III NPC patients screened out according to the treatment response.

NCT ID: NCT06235203 Recruiting - Clinical trials for Recurrent Nasopharyngeal Carcinoma

Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

Start date: May 1, 2024
Phase: Phase 3
Study type: Interventional

A multicenter randomized controlled study of surgery combined with neoadjuvant and adjuvant therapy for locally advanced recurrent nasopharyngeal carcinoma in comparison to surgery combined with adjuvant therapy

NCT ID: NCT06182657 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC

Start date: January 1, 2024
Phase:
Study type: Observational

This study aims to explore the prognostic value of pathological remission after one cycle of induction chemotherapy in locally advanced nasopharyngeal carcinoma, and the change of immune micro-environment after one cycle induction chemotherapy, including the density of immune cells infiltration and tertiary lymphoid structures.

NCT ID: NCT06177301 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC

Start date: December 1, 2023
Phase: Phase 3
Study type: Interventional

The study is being conducted to evaluate the safety and efficacy of tislelizumab combined with GX regimen versus tislelizumab combined with GP regimen in the first-line treatment of nasopharyngeal carcinoma.

NCT ID: NCT06170021 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Occurrence of Radiation-induced Otitis Media in Nasopharyngeal Carcinoma Patients After Intensity Modulated Radiotherapy

Start date: December 6, 2023
Phase:
Study type: Observational [Patient Registry]

This is an observational cohort study to investigate the incidence of radiation-induced otitis media, changes in tubal function and hearing in newly diagnosed nasopharyngeal carcinoma patients without metastasis at multiple time points from baseline to 1 year after radiotherapy.